The Pharmacy Times® Chronic Kidney Disease Resource Center is a comprehensive resource for clinical news and expert insights on issues related to long-term disease of the kidneys leading to renal failure.
July 7th 2025
Patients with chronic kidney disease (CKD) receiving efepoetin alfa demonstrated a response rate of about 75.6%.
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
PBM Challenges and the Evolving Role of Oncology Pharmacists in Community Practices
0.75 Credit / Oncology, Law
View More
Shaping the Future of Renal Cell Carcinoma: A Case-Based Exploration of Emerging Treatment and Improved Patien...
1.5 Credits / Genitourinary Cancer, Oncology, Nephrology
View More
Discipline Decoded: Navigating Pharmacy Law and Disciplinary Cases
1.0 Credit / General Pharmacy, Law
View More
Discipline Decoded: Navigating Pharmacy Law and Disciplinary Cases (Pharmacy Technician Credit)
1.0 Credit / General Pharmacy, Law
View More
FDA Grants Orphan Drug Designation to AND017 for the Treatment of Sickle Cell Disease
October 28th 2024Results demonstrating safety and efficacy in those with anemia in non-dialysis dependent chronic kidney disease and anemia in dialysis-dependent chronic kidney disease were presented at the 2024 American Society of Nephrology Kidney Week.
Read More
Results From the FLOW Trial Show Benefits of Semaglutide on Chronic Kidney Disease
June 24th 2024Benefits of semaglutide on cardiovascular outcomes, such as death, non-fatal myocardial infarction, and non-fatal stoke, were also presented at the session at American Diabetes Association 84th Scientific Sessions.
Read More
Guideline Update: KDIGO 2024 Management of Lupus Nephritis Includes Belimumab for Triple Therapy
January 11th 2024The update includes a recommended triple therapy with belimumab as a first line treatment for class III or IV lupus nephritis following the approvals of belimumab and voclosporin.
Read More
Eleven Potentially Practice-Changing Drugs Were Approved by the FDA in 2023
These drugs have interesting mechanisms, unique use, or may support expanded indications in the future.
Read More
FDA Approves Defencath for Catheter-Related Infections for Those With Kidney Failure
November 15th 2023Taurolidine and heparin (Defencath; CorMedix) is indicated to reduce catheter-related bloodstream infections for adults with kidney failure who are receiving chronic hemodialysis via central venous catheter
Read More